Dual-Biosensor for Five Drugs Detection in Precision Oncology

Area of Science:

• Biomedical Engineering
• Analytical Chemistry
• Oncology

Background:

• Precision medicine in oncology requires monitoring patient-specific drug responses.
• Therapeutic drug monitoring (TDM) is vital for optimizing chemotherapy efficacy and minimizing toxicity.
• Electrochemical biosensors offer portable, rapid, and cost-effective solutions for point-of-care applications.

Purpose of the Study:

• To develop a novel dual-biosensor platform for simultaneous TDM of multiple chemotherapeutic agents.
• To enable real-time, cost-effective drug monitoring for personalized cancer treatment.
• To address patient-specific variability in drug response for improved oncology outcomes.

Main Methods:

• Integration of multi-walled carbon nanotubes (MWCNTs) with cytochrome P450 enzymes (CYP3A4 and CYP2B6).
• Development of a dual-electrode electrochemical sensing platform for simultaneous detection.
• Detection of cyclophosphamide, ifosfamide, etoposide, methotrexate, and 5-fluorouracil within clinically relevant ranges.

Main Results:

• The dual-biosensor platform demonstrated sensitive and selective detection of five key chemotherapeutic drugs.
• Enhanced electron transfer and substrate specificity were achieved through MWCNT-enzyme integration.
• The system successfully monitored drugs individually and in combination under simulated clinical conditions.

Conclusions:

• The proposed dual-biosensor platform provides a portable, rapid, and cost-effective solution for TDM in precision oncology.
• This technology facilitates real-time drug level assessment at the point-of-care, advancing personalized cancer therapy.
• The platform enhances the precision and accessibility of cancer treatment by enabling tailored dosage adjustments.